Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density

Abbey B. Berenson, Mahbubu Rahman, Carmen Radecki Breitkopf, Lian X. Bi

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

OBJECTIVE: Hormonal contraceptives may adversely affect bone mineral density. However, racial differences and the reversibility of these changes are poorly understood. This study measured bone mineral density changes during hormonal contraceptive use and after discontinuation in a triethnic population. METHODS: Bone mineral density was measured every 6 months for up to 3 years in 703 white, African-American, and Hispanic women using oral contraceptives (OCPs), depot medroxyprogesterone acetate (DMPA), or nonhormonal contraceptives, and in 68 DMPA discontinuers for up to 2 additional years. Mixed-model regression analyses were used to estimate the percentage change in bone mineral density for each contraceptive method. RESULTS: Over 3 years, DMPA and OCP users lost more bone mineral density than did nonhormonal contraceptive users (-3.7% and -0.5% compared with +1.9% at lumbar spine, and -5.2% and -1.3% compared with +0.6% at femoral neck, respectively). No differences were observed by race in bone mineral density changes that resulted from DMPA or OCP use. However, DMPA users aged 16-24 years lost more bone mineral density at the spine (4.2% compared with 3.2%, P=.006) and femoral neck (6.0% compared with 4.2%, P=.001) than those aged 25-33 years. After DMPA discontinuation, women who selected nonhormonal contraceptives gained bone mineral density (+4.9% at spine, +3.2% at femoral neck), whereas those who selected OCP recovered spinal (+2.3%) but not femoral neck bone mineral density (-0.7%). CONCLUSION: Use of very-low-dose OCPs may result in a small amount of bone loss. Use of DMPA results in greater bone loss, but this is largely reversible at the spine. Use of very-low-dose OCPs after DMPA discontinuation may slow bone recovery.

Original languageEnglish
Pages (from-to)788-799
Number of pages12
JournalObstetrics and Gynecology
Volume112
Issue number4
DOIs
StatePublished - Oct 2008

Fingerprint

Medroxyprogesterone Acetate
Oral Contraceptives
Bone Density
Contraceptive Agents
Femur Neck
Spine
Bone and Bones
Contraception
Hispanic Americans
African Americans
Regression Analysis

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. / Berenson, Abbey B.; Rahman, Mahbubu; Breitkopf, Carmen Radecki; Bi, Lian X.

In: Obstetrics and Gynecology, Vol. 112, No. 4, 10.2008, p. 788-799.

Research output: Contribution to journalArticle

Berenson, Abbey B. ; Rahman, Mahbubu ; Breitkopf, Carmen Radecki ; Bi, Lian X. / Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. In: Obstetrics and Gynecology. 2008 ; Vol. 112, No. 4. pp. 788-799.
@article{32607edb05db427d99dd29b9f04a60ef,
title = "Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density",
abstract = "OBJECTIVE: Hormonal contraceptives may adversely affect bone mineral density. However, racial differences and the reversibility of these changes are poorly understood. This study measured bone mineral density changes during hormonal contraceptive use and after discontinuation in a triethnic population. METHODS: Bone mineral density was measured every 6 months for up to 3 years in 703 white, African-American, and Hispanic women using oral contraceptives (OCPs), depot medroxyprogesterone acetate (DMPA), or nonhormonal contraceptives, and in 68 DMPA discontinuers for up to 2 additional years. Mixed-model regression analyses were used to estimate the percentage change in bone mineral density for each contraceptive method. RESULTS: Over 3 years, DMPA and OCP users lost more bone mineral density than did nonhormonal contraceptive users (-3.7{\%} and -0.5{\%} compared with +1.9{\%} at lumbar spine, and -5.2{\%} and -1.3{\%} compared with +0.6{\%} at femoral neck, respectively). No differences were observed by race in bone mineral density changes that resulted from DMPA or OCP use. However, DMPA users aged 16-24 years lost more bone mineral density at the spine (4.2{\%} compared with 3.2{\%}, P=.006) and femoral neck (6.0{\%} compared with 4.2{\%}, P=.001) than those aged 25-33 years. After DMPA discontinuation, women who selected nonhormonal contraceptives gained bone mineral density (+4.9{\%} at spine, +3.2{\%} at femoral neck), whereas those who selected OCP recovered spinal (+2.3{\%}) but not femoral neck bone mineral density (-0.7{\%}). CONCLUSION: Use of very-low-dose OCPs may result in a small amount of bone loss. Use of DMPA results in greater bone loss, but this is largely reversible at the spine. Use of very-low-dose OCPs after DMPA discontinuation may slow bone recovery.",
author = "Berenson, {Abbey B.} and Mahbubu Rahman and Breitkopf, {Carmen Radecki} and Bi, {Lian X.}",
year = "2008",
month = "10",
doi = "10.1097/AOG.0b013e3181875b78",
language = "English",
volume = "112",
pages = "788--799",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density

AU - Berenson, Abbey B.

AU - Rahman, Mahbubu

AU - Breitkopf, Carmen Radecki

AU - Bi, Lian X.

PY - 2008/10

Y1 - 2008/10

N2 - OBJECTIVE: Hormonal contraceptives may adversely affect bone mineral density. However, racial differences and the reversibility of these changes are poorly understood. This study measured bone mineral density changes during hormonal contraceptive use and after discontinuation in a triethnic population. METHODS: Bone mineral density was measured every 6 months for up to 3 years in 703 white, African-American, and Hispanic women using oral contraceptives (OCPs), depot medroxyprogesterone acetate (DMPA), or nonhormonal contraceptives, and in 68 DMPA discontinuers for up to 2 additional years. Mixed-model regression analyses were used to estimate the percentage change in bone mineral density for each contraceptive method. RESULTS: Over 3 years, DMPA and OCP users lost more bone mineral density than did nonhormonal contraceptive users (-3.7% and -0.5% compared with +1.9% at lumbar spine, and -5.2% and -1.3% compared with +0.6% at femoral neck, respectively). No differences were observed by race in bone mineral density changes that resulted from DMPA or OCP use. However, DMPA users aged 16-24 years lost more bone mineral density at the spine (4.2% compared with 3.2%, P=.006) and femoral neck (6.0% compared with 4.2%, P=.001) than those aged 25-33 years. After DMPA discontinuation, women who selected nonhormonal contraceptives gained bone mineral density (+4.9% at spine, +3.2% at femoral neck), whereas those who selected OCP recovered spinal (+2.3%) but not femoral neck bone mineral density (-0.7%). CONCLUSION: Use of very-low-dose OCPs may result in a small amount of bone loss. Use of DMPA results in greater bone loss, but this is largely reversible at the spine. Use of very-low-dose OCPs after DMPA discontinuation may slow bone recovery.

AB - OBJECTIVE: Hormonal contraceptives may adversely affect bone mineral density. However, racial differences and the reversibility of these changes are poorly understood. This study measured bone mineral density changes during hormonal contraceptive use and after discontinuation in a triethnic population. METHODS: Bone mineral density was measured every 6 months for up to 3 years in 703 white, African-American, and Hispanic women using oral contraceptives (OCPs), depot medroxyprogesterone acetate (DMPA), or nonhormonal contraceptives, and in 68 DMPA discontinuers for up to 2 additional years. Mixed-model regression analyses were used to estimate the percentage change in bone mineral density for each contraceptive method. RESULTS: Over 3 years, DMPA and OCP users lost more bone mineral density than did nonhormonal contraceptive users (-3.7% and -0.5% compared with +1.9% at lumbar spine, and -5.2% and -1.3% compared with +0.6% at femoral neck, respectively). No differences were observed by race in bone mineral density changes that resulted from DMPA or OCP use. However, DMPA users aged 16-24 years lost more bone mineral density at the spine (4.2% compared with 3.2%, P=.006) and femoral neck (6.0% compared with 4.2%, P=.001) than those aged 25-33 years. After DMPA discontinuation, women who selected nonhormonal contraceptives gained bone mineral density (+4.9% at spine, +3.2% at femoral neck), whereas those who selected OCP recovered spinal (+2.3%) but not femoral neck bone mineral density (-0.7%). CONCLUSION: Use of very-low-dose OCPs may result in a small amount of bone loss. Use of DMPA results in greater bone loss, but this is largely reversible at the spine. Use of very-low-dose OCPs after DMPA discontinuation may slow bone recovery.

UR - http://www.scopus.com/inward/record.url?scp=54549108234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54549108234&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e3181875b78

DO - 10.1097/AOG.0b013e3181875b78

M3 - Article

VL - 112

SP - 788

EP - 799

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 4

ER -